SCHEMBL13638641

SCHEMBL13638641

Nc1nc(N)c(C(=O)c2ccc(OC(F)F)cc2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
NPC1 O15118 5/20 0.51
CDK5 Q00535 8/20 0.48
CDK5R1 Q15078 8/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 1/20 0.48
ALOX15 P16050 1/20 0.48
GFER P55789 1/20 0.48
ADAM17 P78536 1/20 0.48
RAB9A P51151 3/20 0.47
CLK1 P49759 1/20 0.47
CCNA2 P20248 7/20 0.44
CDK2 P24941 7/20 0.44
TUBB8B A6NNZ2 1/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43
TUBB2A Q13885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638606 0.82 MEN1 (0.67) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL4512246 0.80 CCNA2 (0.61) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL25278128 0.80 MEN1 (0.80) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL4469318 0.80 MEN1 (0.84) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL13638608 0.79 CDK5 (0.55) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL4469916 0.79 MEN1 (0.56) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL25223674 0.79 MEN1 (0.68) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL25609929 0.79 MEN1 (0.68) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL4473389 0.78 CCNA2 (0.67) MEN1KMT2ANPC1CDK5CDK5R1
SCHEMBL4466121 0.78 MEN1 (0.80) MEN1KMT2ANPC1CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A MEN1 2737/4885KMT2A 2234/4885NPC1 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.